GZMB and neoplasm: After the addition of nivolumab to this model, T cell activation marker IFNG, GZMB and PRF1 were significantly increased, and the tumor cells also underwent significant apoptosis, indicating that this model could successfully mimic the response process of tumor immunotherapy and was expected to be applied to evaluate the efficacy and sensitization methods of ICB therapy.